ClinicalTrials.gg
Active, not recruitingNCT04522323Updated Jul 25, 2025

A Study to Evaluate MEDI5752 and Axitinib in Subjects With Advanced Renal Cell Carcinoma

A Phase 1 interventional study of MEDI5752 and Axitinib in Advanced Renal Cell Carcinoma, sponsored by MedImmune LLC. Active, not recruiting at 20 sites in 4 countries. Open to participants aged 18 Years to 101 Years. Per ClinicalTrials.gov, last updated 2025-07-25.

Sponsored by MedImmune LLC (part of AstraZeneca) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Sep 2025, 1 year 1 month ago, but the record still lists the study as active, not recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
67
Allocation
Non-randomized
Ages
18 Years to 101 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 15 studies in Carcinoma, Renal Cell by AstraZeneca — 2 open to participants now, 7 under way, 2 of them phase 3. Carcinoma, Renal Cell · AstraZeneca.

Enrollment
6th of 12
67 · median 64
Started
2020
with 1 other
Phase 1
5 of 15
none open now
Registered
9th of 15
by date

Among the 15 studies in Carcinoma, Renal Cell by AstraZeneca, this one is the 6th largest by enrollment of the 12 interventional ones that give a count, is one of 2 that started in 2020, is one of 5 in phase 1, and was the 9th registered.

Carcinoma, Renal Cell

2,039 studies on the registry are indexed under Carcinoma, Renal Cell; 395 are open to participants now.

Browse Carcinoma, Renal Cell studies →

Open to participants now

2 of the 15 studies in Carcinoma, Renal Cell by AstraZeneca are open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 307 Carcinoma, Renal Cell studies recruiting now, 254 (83%) set no upper age limit and 18 (6%) stop at 75 or younger; 20 take children under 18; 19 take healthy volunteers.

This study: 18 Years to 101 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies in Carcinoma, Renal Cell by AstraZeneca, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate MEDI5752 in combination with Lenvatinib (or Axitinib), in subjects with advanced renal cell carcinoma.

Read the detailed description

The purpose of this Phase 1b study is to evaluate the safety, tolerability, pharmacokinetics, immunogenicity, and antitumor activity of MEDI5752 in combination with Lenvatinib (or Axitinib) in subjects with advanced renal cell carcinoma.

03

Conditions studied

  • Advanced Renal Cell Carcinoma

Keywords

  • renal cell carcinoma
  • MEDI5752
  • PD-1/CTLA-4 bispecific
  • PD-1
  • CTLA-4
  • bispecific
  • axitinib
  • lenvatinib
04

Who can participate

Ages eligible
18 Years to 101 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 18 at the time of screening
  • Body weight > 35 kg
  • Written
  • or cytologically proven advanced RCC with clear cell component
  • Advanced RCC not previously treated in that setting
  • Provision of tumor material (≥ 5 unstained slides or tissue block) from an archival or fresh tissue sample
  • performance status of 0 or 1
  • Subjects must have at least 1 according to v1.1
  • ≥ 12 weeks
  • Adequate organ and marrow function
  • Female subjects of must have negative pregnancy test at screening and prior to each administration of product, and must use at least one highly effective method of .
  • Strongly recommend nonsterilized male partners of female subjects of childbearing potential use a male condom plus spermicide from screening to 7.6 months after the last dose of MEDI5752 and 30 days after the last dose of lenvatinib.

Exclusion criteria

Exclusion Criteria:

  • Any condition that, in the opinion of the investigator, would interfere with evaluation of the product or interpretation of subject safety or study results
  • Concurrent enrollment in another clinical study, unless it is an observational study.
  • Previous treatment with mTOR inhibitors, , PD-L1, or CTLA-4 inhibitors for RCC or any other immune checkpoint inhibitor
  • Previous treatment with VEGF inhibitors
  • Evidence of the following infections: active infection including tuberculosis, , chronic or active or chronic or active
  • History of organ transplant
  • Active or prior documented or inflammatory disorders
  • Current or prior use of medication within 14 days prior to the first dose of investigational product.
  • Poorly controlled blood pressure (BP) defined as systolic BP ≥ 140/90 mmHg at screening and not able to be controlled prior to Cycle 1 Day 1 and any change in antihypertensive medications within 1 week prior to Cycle 1 Day 1.
  • Thromboembolic (arterial or venous) events within previous 6 months
  • Any concurrent therapy for cancer
  • Receipt of within 30 days prior to the first dose of investigational product
  • Known allergy or to investigational product(s) or any of the of the investigational product(s)
  • Untreated or progressive CNS disease, any , or cord compression
  • History of another primary
  • Unresolved toxicities from previous anticancer therapy
  • Major surgery within 4 weeks prior to enrollment or radiation therapy within 2 weeks prior to enrollment or has not recovered from AEs due to prior treatment
  • Female subjects must not breastfeed and must not donate, or retrieve for their own use, ova from screening to 3 months after the last dose of MEDI5752 and 30 days after the last dose of lenvatinib.
  • History of arrhythmia which is symptomatic or requires treatment, symptomatic or uncontrolled atrial fibrillation despite treatment, or asymptomatic sustained ventricular tachycardia
  • Uncontrolled intercurrent illness within the last 6 months prior to enrollment
  • gastrointestinal abnormality
  • Serious nonhealing wound, ulcer, or bone fracture
  • Has clinically significant hemoptysis (at least 0.5 teaspoon of bright red blood) or tumor bleeding within 2 weeks before the first dose of investigational product
  • Radiographic evidence of major blood vessel invasion/infiltration/encasement
Terms in these criteria, in plain language(22)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
67 participants (actual)

Study arms

  • Experimental
    Dose Exploration

    The Dose exploration Phase is made up of Part A, B and Part C. Part A will evaluate the safety and tolerability of MEDI5752 in combination with Axitinib (2 patients), and Part B and C will evaluate the safety and tolerability of MEDI5752 in combination with Lenvatinib (\~72 patients)

    Biological: MEDI5752 · Drug: Axitinib · Drug: Lenvatinib

  • Experimental
    Dose Expansion

    Evaluate safety and anti-tumor activity of MEDI5752 in combination with Lenvatinib (\~105 patients )

    Biological: MEDI5752 · Drug: Axitinib · Drug: Lenvatinib

Interventions

06

What researchers measure

Primary outcomes

  1. Number of subjects experiencing adverse events (AEs)/serious adverse events (SAEs)

    The primary safety endpoint is as assessed by the number of subjects with adverse events and serious adverse events (SAEs) graded per NCI CTCAE v5.0.

    Time frame: Informed consent through 90-Day Post Last Dose.

  2. Number of Participants With Dose Limiting Toxicities (DLT) of MEDI5752 and Lenvatinib (or Axitinib) during the Dose Exploration period.

    Determine the MTD and recommended Phase 2 dose (RP2D) of the combination of MEDI5752 and Lenvatinib. A dose limiting toxicity (DLT) is defined as MEDI5752 treatment-related AE of any Grade 3 or higher toxicity (as defined in the protocol) CTCAE v5.0.

    Time frame: Informed consent through the first 21 days of treatment with MEDI5752 and Lenvatinib (or Axitinib) in the Dose Exploration Period.

  3. Number of subjects experiencing adverse events (AEs) leading to discontinuation.

    The primary safety endpoint is as assessed by the number of subjects with serious adverse events (SAEs) graded per NCI CTCAE v5.0.

    Time frame: Informed consent through 90-Day Post Last Dose.

  4. Number of subjects experiencing abnormal laboratory evaluations.

    The primary safety endpoint is as assessed by the number of subjects experiencing changes in laboratory evaluations from baseline.

    Time frame: Informed Consent through 90 post treatment date.

  5. Number of subjects experiencing changes in vital signs reported as Adverse Events.

    The primary safety endpoint is assessed by the change in vital signs from baseline.

    Time frame: Informed consent through 90-Day Post Last Dose

  6. Number of subjects experiencing abnormal electrocardiograms (ECG) reported as Adverse Events.

    The primary safety endpoint is as assessed by the change in ECG parameters from baseline.

    Time frame: Informed consent through 90-Day Post Last Dose

  7. Preliminary antitumor activity of MEDI5752 combined with Lenvatinib (or Axitinib) by Objective response rate per RECIST version (v) 1.1.

    The primary efficacy endpoint is assessed by the antitumor activity of MEDI5752 combined with Lenvatinib.

    Time frame: First subject enrolled through 18 months from last subject enrolled, an average of 30 months.

Secondary outcomes

  1. Antitumor activity of MEDI5752 combined with Lenvatinib by measuring the progression free survival (PFS) according to RECIST v1.1.

    The endpoint for assessment of PFS is defined as the time from the first dose of treatment until the documentation of PD or death due to any cause, whichever occurs first.

    Time frame: Last Subject Enrolled through study completion, an average of 48 months.

  2. Antitumor activity of MEDI5752 combined with Lenvatinib by measuring the Best Overall Response (BOR) according to RECIST v1.1.

    The endpoint for assessment of BOR will be based on all post-baseline disease assessments that occur prior to the initiation of subsequent anticancer treatment

    Time frame: First subject enrolled through 18 months from last subject enrolled, an average of 30 months.

  3. Antitumor activity of MEDI5752 combined with Lenvatinib by measuring the Disease Control Rate (DCR).

    The endpoint for assessment of DCR is measured by the proportion of subjects with a BOR of confirmed CR, PR, or SD.

    Time frame: Informed Consent through the date of first documented progression, end of study, date of death, or two years after last subject starts treatment whichever should occur first

  4. Antitumor activity of MEDI5752 combined with Lenvatinib by measuring the Duration of Response (DOR) according to RECIST v1.1.

    The endpoint for assessment of DOR is measured by the duration from the first documented OR to the first documented PD or death due to any cause, whichever occurs first.

    Time frame: Informed Consent through the date of first documented progression, end of study, date of death, or two years after last subject starts treatment whichever should occur first

  5. Antitumor activity of MEDI5752 combined with Lenvatinib by measuring the Time to Response (TTR) according to RECIST v1.1.

    The endpoint for assessment of TTR is defined as the time from the first dose of treatment until the first documentation of an OR.

    Time frame: Informed Consent through the date of first documented progression, end of study, date of death, or two years after last subject starts treatment whichever should occur first

  6. Pharmacokinetics of MEDI5752: Cmax

    The endpoints for the assessment of PK of MEDI5752 include individual MEDI5752 concentrations at different time points after administration.

    Time frame: Day 1, 8, 15, 22, 64 and then Day 1 of every other cycle

  7. Pharmacokinetics of MEDI5752: AUC

    The endpoints for the assessment of PK of MEDI5752 include individual MEDI5752 concentrations at different time points after administration.

    Time frame: Day 1, 8, 15, 22, 64 and then Day 1 of every other cycle

  8. Pharmacokinetics of MEDI5752: Cmin

    The endpoints for the assessment of PK of MEDI5752 include individual MEDI5752 concentrations at different time points after administration.

    Time frame: Day 1, 8, 15, 22, 64 and then Day 1 of every other cycle

  9. Pharmacokinetics of MEDI5752: t 1/2

    The endpoints for the assessment of PK of MEDI5752 include individual MEDI5752 concentrations at different time points after administration.

    Time frame: Day 1, 8, 15, 22, 64 and then Day 1 of every other cycle

  10. Pharmacokinetics of MEDI5752: Clearance

    The endpoints for the assessment of PK of MEDI5752 include individual MEDI5752 concentrations at different time points after administration.

    Time frame: Day 1, 8, 15, 22, 64 and then Day 1 of every other cycle

  11. Immunogencity of MEDI572: Incidence of ADAs against MEDI5752

    The endpoints for the immunogenicity of MEDI5752 include the number of subjects who develop detectable anti-drug antibodies (ADAs) to MEDI5752.

    Time frame: Day 1, 8, 15, 22, 30, 64 and then Day 1 of every other cycle

07

Study locations

20 sites
  • Research Site
    Washington D.C., District of Columbia 20007, United States
  • Research Site
    Fort Myers, Florida 33908, United States
  • Research Site
    St Louis, Missouri 63156, United States
  • Research Site
    New York, New York 10065, United States
  • Research Site
    Cleveland, Ohio 44195, United States
  • Research Site
    Hershey, Pennsylvania 17033, United States
  • Research Site
    Nashville, Tennessee 37232, United States
  • Research Site
    Frankston, 3199, Australia
  • Research Site
    Waratah, 2298, Australia
  • Research Site
    Villejuif, 94805, France
  • Research Site
    Barcelona, 08003, Spain
  • Research Site
    Barcelona, 08025, Spain
  • Research Site
    Barcelona, 08035, Spain
  • Research Site
    Barcelona, 08908, Spain
  • Research Site
    Córdoba, 14004, Spain
  • Research Site
    Madrid, 28040, Spain
  • Research Site
    Madrid, 28041, Spain
  • Research Site
    Sabadell, 08208, Spain
  • Research Site
    Seville, 41013, Spain
  • Research Site
    Valencia, 46009, Spain
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure

Access criteria: When a request has been approved AstraZeneca will provide access to the deidentified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure

Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2020 (actual). Primary completion is estimated for Sep 2025, 61 months after the start.

Of 138 industry-sponsored phase 1 interventional studies under Carcinoma, Renal Cell, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 32 and three quarters within 63. This study's planned 61 months is above that.

Counting every sponsor, half of 219 studies reached it within 50 months; a quarter within 32 and three quarters within 72.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 22, 2020
First posted
Aug 21, 2020
StartActual
Aug 5, 2020
Primary completionEst.
Sep 26, 2025
CompletionEst.
Sep 26, 2025
Last update
Jul 25, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 25, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04522323
Lead sponsor
MedImmune LLC
Responsible party
Sponsor
First posted
Aug 21, 2020
Start date
Aug 5, 2020
Primary completion
Sep 26, 2025 (estimated)
Completion
Sep 26, 2025 (estimated)
Last update
Jul 25, 2025

Study contacts

AstraZeneca Early Oncology
study director · AstraZeneca

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Volrustomig

Start the discussion